Open-source Drug Discovery is an adaptation to drug R&D of the very successful open-source software model. It has inspired the redesign of the aging pharmaceutical R&D model, and has been used to energize drug research into neglected and rare diseases. Its major features and benefits are:
Enhanced innovation through broader cross-pollination; Much lower costs from leveraging networks of volunteers; Greater speed from faster decision-making; Extremely light and efficient organization. In the last year, the open-source drug R&D model has delivered its first approved drugs (for malaria), and built-up a significant pipeline (for many rare and neglected diseases). There will be speakers from institutions including CSIR (India), WHO, NIH and GlaxoSmithKline.
Enhanced innovation through broader cross-pollination; Much lower costs from leveraging networks of volunteers; Greater speed from faster decision-making; Extremely light and efficient organization. In the last year, the open-source drug R&D model has delivered its first approved drugs (for malaria), and built-up a significant pipeline (for many rare and neglected diseases). There will be speakers from institutions including CSIR (India), WHO, NIH and GlaxoSmithKline.
